BOLALARDA SURUNKALI BUYRAK KASALLIGIDA ENDOTELIAL DISFUNKSIYA: PATOGENETIK MEXANIZMLARI, DIAGNOSTIKASI VA KORREKSIYASINING ZAMONAVIY YONDASHUVLARI
Аннотация
Surunkali buyrak kasalligi (SBK) bolalarda buyrak funksiyasining bosqichma-bosqich pasayishi bilan kechuvchi va ko‘plab tizimli asoratlarni yuzaga keltiruvchi progressiv patologik holat hisoblanadi. Zamonaviy tadqiqotlarda SBKning muhim asoratlaridan biri sifatida endotelial disfunksiya qaralib, u yurak-qon tomir tizimi zararlanishining erta patogenetik mexanizmlaridan biri sifatida baholanmoqda. Endotelial funksiyaning buzilishi azot oksidi (NO) almashinuvining izdan chiqishi, oksidlovchi stress, surunkali yallig‘lanish va uremik toksinlarning to‘planishi bilan bog‘liq.
Библиографические ссылки
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International. 2024;105(4S):S117–S314.
Warady BA, Chadha V. Chronic kidney disease in children: the global perspective. Pediatric Nephrology. 2007;22(12):1999–2009.
Mitsnefes MM. Cardiovascular disease in children with chronic kidney disease. Journal of the American Society of Nephrology. 2012;23(4):578–585.
Shroff R, Weaver DJ Jr, Mitsnefes MM. Cardiovascular complications in children with chronic kidney disease. Nature Reviews Nephrology. 2019;15:641–654.
Schaefer F, Warady BA. Cardiovascular risk factors in children with chronic kidney disease. Pediatric Nephrology. 2017;32:2015–2027.
Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115(10):1285–1295.
Brunner H, Cockcroft JR, Deanfield J, et al. Endothelial function and dysfunction. Journal of Hypertension. 2005;23(2):233–246.
Baylis C. Nitric oxide deficiency in chronic kidney disease. Kidney International. 2008;74(5):522–525.
Hsu CN, Tain YL. Regulation of nitric oxide production in chronic kidney disease and hypertension. International Journal of Molecular Sciences. 2021;22(22):12328.
Kielstein JT, Zoccali C. Asymmetric dimethylarginine: a cardiovascular risk factor and a potential target for intervention in renal disease. Journal of the American Society of Nephrology. 2005;16(9):2449–2461.
Fliser D, Kronenberg F, Kielstein JT, et al. Asymmetric dimethylarginine and progression of chronic kidney disease. Journal of the American Society of Nephrology. 2005;16(8):2456–2461.
Dhaun N, Webb DJ. Endothelins in cardiovascular biology and therapeutics. Nature Reviews Cardiology. 2019;16:491–502.
Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Canadian Journal of Physiology and Pharmacology. 2008;86(8):485–498.
Yilmaz MI, Sonmez A, Ortiz A, et al. Inflammation and endothelial dysfunction in chronic kidney disease. Clinical Journal of the American Society of Nephrology. 2011;6(6):161–168.
Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. Blood Purification. 2006;24(1):1–3.
Drożdż D, Kwinta P, Sztefko K, et al. Oxidative stress biomarkers and endothelial dysfunction in children with chronic kidney disease. Oxidative Medicine and Cellular Longevity. 2018;2018:1619293.
Смирнов А.В., Добронравов В.А., Румянцев А.Ш. Национальные рекомендации по хронической болезни почек: основные положения. Нефрология.
Шутов А.М. Хроническая болезнь почек и сердечно-сосудистый риск. Нефрология.
Мухин Н.А., Моисеев В.С. Роль эндотелиальной дисфункции в развитии сердечно-сосудистых осложнений при заболеваниях почек. Клиническая медицина.
